Kerendia

Finerenone, the active ingredient in Kerendia, is a mineralocorticoid receptor antagonist (non‑steroidal) presented as a tablet for oral use. It is employed to treat chronic kidney disease associated with type 2 diabetes and to help manage hypertension in adult patients.

GNH USA supplies Kerendia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to global healthcare providers.

Kerendia (finerenone) is indicated for conditions involving mineralocorticoid receptor‑mediated renal and cardiovascular pathology.

- Chronic kidney disease associated with type 2 diabetes: slows decline in kidney function and reduces albuminuria. - Hypertension: contributes to blood‑pressure reduction as part of a comprehensive regimen. - Cardiovascular risk in CKD patients: lowers the incidence of major adverse cardiovascular events.

Finerenone may cause a range of adverse reactions, most of which are related to its impact on electrolyte balance and renal function.

Common Side Effects: - Hyperkalaemia: elevated serum potassium levels. - Hypotension: low blood pressure, especially when combined with other antihypertensives. - Dizziness or light‑headedness. - Nausea or gastrointestinal discomfort. - Headache. - Fatigue.

Serious or Rare Side Effects: - Severe hyperkalaemia requiring medical intervention. - Acute kidney injury or rapid decline in renal function. - Allergic reactions such as rash, pruritus, or angio‑edema. - Significant elevation of liver enzymes. - Electrolyte disturbances beyond potassium, e.g., hyponatraemia.

When prescribing finerenone, clinicians should consider several safety measures to minimise risk.

- Monitor serum potassium: check levels before initiation and periodically thereafter. - Assess renal function: evaluate eGFR at baseline and during therapy. - Use caution in patients with diabetes: monitor glucose control and renal markers. - Avoid concomitant use with other potassium‑sparing agents unless closely supervised. - Adjust dose in moderate hepatic impairment: consider lower starting dose. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Finerenone can interact with several drug classes, influencing potassium balance and renal function.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): risk of severe hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase finerenone exposure. - ACE inhibitors or ARBs combined without monitoring: heightened potassium elevation.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function. - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Other antihypertensives: monitor blood pressure for additive effects. - Diuretics that affect volume status: adjust electrolytes as needed.